Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil versus sufentanil for postoperative nausea and vomiting after gynecological laparoscopy
ChiCTR2400085487Phase 4Not yet recruiting
- Sponsor
- Zibo City Central Hospital
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of remifentanil and sufentanil in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Zibo City Central Hospital. Primary endpoint: Overall postoperative nausea and vomiting incidence at 24 hours. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
remifentanilsufentanil
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2400085487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085487.